We invest in early-stage in life science technologies that address significant healthcare problems in poorly served markets. These are opportunities that have the potential to change the societal healthcare equation. Most often, this means the development of products based on biotechnology or pharmaceutical chemistry but we are receptive to opportunities in medical devices, computational biology and genomics.